Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months

Dementia,In,Senior,People.,Memory,Loss.,Awareness,Of,Alzheimer's,,Parkinson's

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an oral small molecule that could potentially treat early Alzheimer’s disease.

The data were presented at the 2025 Alzheimer’s Association International Conference.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.